News | September 17, 2024
Wacker collaborates with MinervaX for prophylactic vaccine targeting Group B streptococcus
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Total investment incurred for setting up the new R&D Rs 250 crore
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
The partnership aims to revolutionize Artificial Intelligence in health research with innovative data platform
Agreement further expands Aptar Pharma’s leading respiratory portfolio
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
The company has entered into a long-term lease and operations and management agreement with Sree Chand Specialty Hospital, situated in Kannur
The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
Subscribe To Our Newsletter & Stay Updated
